Voyager Therapeutics Inc buy Quitte
Zusammenfassung
Diese Einschätzung wurde am 20.04.18 mit einem Endkurs von 16,63 € beendet. Abwärts ging es seit Start der Einschätzung mit Voyager Therapeutics Inc. Verglichen mit dem Start ergibt sich eine Rendite von -20,10 %. Quitte hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Voyager Therapeutics Inc | 0,83 % | 0,83 % | -34,92 % | 146,58 % |
| iShares Core DAX® | 0,05 % | 5,59 % | 14,40 % | 19,77 % |
| iShares Nasdaq 100 | 1,81 % | 7,45 % | 34,92 % | 57,24 % |
| iShares Nikkei 225® | 2,18 % | 2,82 % | 11,12 % | 8,87 % |
| iShares S&P 500 | 1,04 % | 4,97 % | 27,63 % | 48,79 % |
Kommentare von Quitte zu dieser Einschätzung
In der Diskussion Voyager Therapeutics Inc diskutieren
heiße Eisen im Feuer
https://seekingalpha.com/article/4113624-4-biotech-stocks-worth-buying-pullback
Shares of this gene therapy pioneer peaked at the $26 mark before rapidly regressing to $20. I think this one especially is a candidate for a swift snap back. In early September, I followed up with an update after it was clear that candidate VY-AADC01 was a winner in treating patients with Advanced Parkinson's disease. Dose and time-dependent improvements were observed on several measures of motor function after one-time administration of the drug candidate, and I noted that it was fascinating to envision a solution that allows patients' medications to be significantly reduced (by a mean of 42% in the third cohort versus 34% in the second and 14% in the first).
Management guided for a pivotal phase 2/3 program to be initiated late in the year with the first patient to be enrolled and dosed in the first half of 2018. The fact that the company hasn't engaged in a secondary offering yet raises eyebrows, and I note that Sanofi (NYSE:SNY) already owns 10% of shares outstanding.
As of June 30th, the company had cash and equivalents of $141.3 million, and management has guided for finishing the year with $90 to $100 million on the balance sheet. This compares favorably to the GAAP net loss of $18.9 million for the quarter.
The company also has other promising irons in the fire, with IND-enabling studies for VY-SOD101 for the treatment of ALS caused by mutations in the superoxide dismutase 1 gene (SOD1) progressing and the application to be filed later in the year or in early 2018. I believe that management's tentative hypothesis that a single intrathecal injection could substantially reduce levels of the toxic protein in the central nervous system to slow disease progression holds water.
On the con side, I imagine the method of administration for VY-AADC01 has the possibility of hindering adoption.
I consider this one a revaluation play, believing it should increase as the market appreciates the strength of the data and realizes that the age of gene therapy truly is arriving. The company is transitioning to a late-stage gene therapy concern and the reduced risk brought on by such positive data should be taken into account.